Concentration of low‑density lipoproteins (LDL) is significantly reduced after nilotinib discontinuation
Metadatos
Mostrar el registro completo del ítemAutor
Roa Chamorro, Ricardo; Puerta Puerta, José Manuel; Torres Quintero, Lucía; Jaén Águila, Fernando; González Bustos, Pablo; Rodríguez‑Gil, Miguel Ángel; Mediavilla García, Juan DiegoEditorial
Springer Nature
Fecha
2023-07-21Referencia bibliográfica
Roa Chamorro, R. et. al. Sci Rep 13, 11781 (2023). [https://doi.org/10.1038/s41598-023-39057-x]
Resumen
Dyslipidemia is a frequent side effect associated with nilotinib treatment. Patients with chronic
myeloid leukemia (CML) under treatment with nilotinib who develop dyslipidemia have been shown
to have a higher risk of presenting atherosclerotic cardiovascular disease (ACVD). Therapeutic
discontinuation in selected individuals could be a strategy in order to prevent the development of
ACVD. Observational study of patients with CML under nilotinib treatment. The lipid values were
gathered before starting with nilotinib and after 3 months. Such values were also measured before
discontinuation in patients who suspended nilotinib treatment, as well as 3 and 12 months later.
32 patients were included, 19 of them treated in monotherapy with nilotinib. The concentrations
of total cholesterol and low-density lipoproteins (LDL) increased significantly after 3 months of
treatment (27.29 mg/dL ± 22.88, p < 0.01). Of the total number of patients treated, 12 discontinued
the treatment. LDL concentration was significantly reduced after 3 months of the nilotinib
discontinuation (− 27.58 mg/dL ± 38.30, p = 0.030), remaining substantially lower after 12 months,
compared to the time previous to discontinuation (− 24.58 mg/dL ± 37.31, p = 0.043). Nilotinib
suspension reduces significantly LDL concentrations. These data support the strategy of therapeutic
discontinuation in order to prevent future cardiovascular complications, especially in patients with
prior cardiovascular risk factors.